Abstract 227P
Background
Invasive ductal breast cancer (IDC) is a heterogeneous disease. Staging and immunohistochemistry allow adequate treatment but it is not yet ideal. Women with Luminal B tumors show an erratic response to treatment. The aim of this study is to improve the prognostic stratification of Luminal B patients.
Methods
A prospective study with 234 women with IDC, grouped by TNM and immunohistochemistry in subtypes Luminal A and B, HER2 and Triple Negative, for analysis of survival and its correlations with neutrophils/lymphocytes by hemogram. An equitable selection of 1/3 of these patients, between stages and subtypes, was analyzed for correlations of serum expressions of 7 CC-chemokines, 6 CXC-chemokines, and 3 cytokines; and analysis of TCD8+ and TCD4/FOXP3+ lymphocytes in the tumor microenvironment.
Results
Overall survival was significantly dependent on staging and tumor subtypes. There was correlation of age with IL-6 (r=+0.243;p=0.037), IL-10 (r=+0.304;p=0.009) and IP10/CXCL10 (r=+0.412;p=0.011). There was a correlation between BMI and the chemokine Rantes/CCL5 (r =-0.334; p=0.009). Kaplan-Meier curves showed that Luminal B patients with neutrophil/lymphocyte ratio >2 (Log-Rank p=0.005), or lower expression of ENA78/CXCL5 (≤239.69pg/ml) (Log-Rank p=0.016) and high expression of MIP1β/CCL4 (>34.53pg/ml) (Log-Rank p=0.017) in the serum, or TCD4 lymphocytes >30% (Log-Rank p=0.027) and TCD4+TCD8 lymphocytes >75% (Log-Rank p=0.033) infiltrators in the tumor microenvironment had higher risk of metastasis/death.
Conclusions
Luminal B patients can be better stratified both by blood count and/or serum chemokine analysis and by infiltration of T lymphocytes into the tumor, opening new target-specific therapeutic approaches, in addition to chemotherapy and hormone therapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.